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ORIGINAL ARTICLE
Relationship Between Blood Pressure and 
Incident Cardiovascular Disease
Linear and Nonlinear Mendelian Randomization Analyses
Rainer Malik, Marios K. Georgakis , Marijana Vujkovic , Scott M. Damrauer , Paul Elliott , Ville Karhunen ,  
Alice Giontella, Cristiano Fava , Jacklyn N. Hellwege , Megan M. Shuey, Todd L. Edwards, Tormod Rogne,  
Bjørn O. Åsvold , Ben M. Brumpton , Stephen Burgess, Martin Dichgans , Dipender Gill
ABSTRACT: Observational studies exploring whether there is a nonlinear effect of blood pressure on cardiovascular disease 
(CVD) risk are hindered by confounding. This limitation can be overcome by leveraging randomly allocated genetic variants 
in nonlinear Mendelian randomization analyses. Based on their association with blood pressure traits in a genome-wide 
association study of 299 024 European ancestry individuals, we selected 253 genetic variants to proxy the effect of modifying 
systolic and diastolic blood pressure. Considering the outcomes of incident coronary artery disease, stroke and the combined 
outcome of CVD, linear and nonlinear Mendelian randomization analyses were performed on 255 714 European ancestry 
participants without a history of CVD or antihypertensive medication use. There was no evidence favoring nonlinear relationships 
of genetically proxied systolic and diastolic blood pressure with the cardiovascular outcomes over linear relationships. For 
every 10-mm Hg increase in genetically proxied systolic blood pressure, risk of incident CVD increased by 49% (hazard ratio, 
1.49 [95% CI, 1.38–1.61]), with similar estimates obtained for coronary artery disease (hazard ratio, 1.50 [95% CI, 1.38–
1.63]) and stroke (hazard ratio, 1.44 [95% CI, 1.22–1.70]). Genetically proxied blood pressure had a similar relationship with 
CVD in men and women. These findings provide evidence to support that even for individuals who do not have elevated 
blood pressure, public health interventions achieving persistent blood pressure reduction will be of considerable benefit in 
the primary prevention of CVD. (Hypertension. 2021;77:00–00. DOI: 10.1161/HYPERTENSIONAHA.120.16534.) 
• Data Supplement
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More than 1 billion people worldwide experience hyper-tension,1 which is estimated to account for >20% of cardiovascular disease (CVD).2 Meta-analyses of 
randomized controlled trials have shown that a 10-mm Hg 
reduction in systolic blood pressure (SBP) is associated 
with a 15% to 20% reduction in the risk of coronary artery 
disease (CAD) and a 25% to 30% reduction in the risk of 
stroke.3 As such, blood pressure lowering is one of the most 
effective strategies for reducing the burden of CVD.4,5
See Editorial, pp xxx–xxx
Large observational studies have previously 
explored the relationship between blood pressure 
and cardiovascular risk, potentially identifying linear 
associations in individuals free of CVD at baseline6,7 
but J-shaped associations both in the general pop-
ulation8 and in patients with a history of CAD9 and 
stroke.10 However, it is difficult to make causal con-
clusions about the effects of altering blood pressure 
from such data because any identified associations 
may be susceptible to confounding from unknown or 
unmeasured factors. For the patients with elevated 
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Pressure Intervention Trial (SPRINT) trial, SBP low-
ering to <120 mm Hg as compared with 140 mm Hg 
resulted in fewer major cardiovascular events.11 How-
ever, no high-quality clinical trials have investigated 
the effect of blood pressure lowering below this level. 
Excessive blood pressure reduction in patients with 
atherosclerotic disease can reduce organ perfusion 
and increase CVD risk.12 Insight into the shape of the 
relationship between blood pressure and CVD risk 
is, therefore, critical for informing optimal prevention 
strategies.
In the Mendelian randomization (MR) paradigm, 
genetic variants can be used as proxies for study-
ing the effect of varying blood pressure.13 In the 
same way as treatment allocation in a randomized 
controlled trial setting, random allocation of genetic 
variants means that they are unlikely to be affected 
by confounding from environmental factors.14 Recent 
methodological developments have allowed for 
MR investigation into the shape of the relationship 
between risk factors and outcomes.15–17 In this study, 
we use MR to investigate the shape of the relation-
ship between genetically proxied blood pressure and 
incident CVD in a general population without a his-
tory of CVD or antihypertensive medication use. Our 
analyses aim to provide novel insight that can be 
used to inform public health strategies toward the 
primary prevention of CVD.
METHODS
All data supporting the findings of this study are available 
from the corresponding author upon reasonable request. 
The UK Biobank study was approved by the North West 
Multicentre Research Ethics Committee, and all participants 
provided informed consent. All variants used as instruments 
in this study and their genetic association estimates are pro-
vided in the Data Supplement. All results from the analyses 
performed in this work are presented in the main article or 
its Data Supplement. This article has been reported based on 
recommendations by the STROBE-MR Guidelines (Checklist 
in the Data Supplement).18 The study protocol and details 
were not preregistered.
UK Biobank
The UK Biobank cohort is comprised of ≈500 000 people (94% 
of self-reported European ancestry) aged 40 to 69 years at 
baseline and recruited between 2006 and 2010 at 22 assess-
ment centers throughout the United Kingdom. Participants 
were followed up until January 1, 2018, or their date of death. 
Along with genotyping, the resource has information on clinical 
measurements, assays of biological samples, and self-reported 
health behavior. Moreover, it is supplemented by linkage with 
electronic health records including hospital inpatient data, mor-
tality data, and cancer registries.19
For the exposures of interest, SBP and diastolic blood pres-
sure (DBP), data were collected using an automated reading 
when participants attended the assessment center for baseline 
measurements (UK Biobank fields 4080 for SBP and 4079 for 
DBP). When multiple baseline measurements were available, 
the mean of the measured values was used.
As our primary outcomes, we selected a combined inci-
dent cardiovascular end point of CAD and stroke (referred to 
hereafter as CVD), incident CAD, and incident stroke. We used 
hospitalization-based International Classification of Diseases, 
Tenth Revision, and Office of Population Censuses and 
Nonstandard Abbreviations and Acronyms
CAD coronary artery disease
CVD cardiovascular disease
DBP diastolic blood pressure
HR hazard ratio
MR Mendelian randomization
SBP systolic blood pressure
Novelty and Significance
What Is New?
• Recent methodological developments have enabled 
randomly allocated genetic variants to be leveraged 
in nonlinear Mendelian randomization analyses that 
explore the shape of the relationship between a risk 
factor and an outcome.
• Performing linear and nonlinear Mendelian random-
ization analyses in 255 714 European ancestry UK 
Biobank participants without a history of cardiovas-
cular disease or antihypertensive medication use, this 
study found no evidence favoring nonlinear relation-
ships of genetically proxied systolic and diastolic blood 
pressures with incident coronary artery disease, stroke, 
or a combined end point.
What Is Relevant?
• At all levels of blood pressure, public health interven-
tions achieving persistent blood pressure reduction are 
likely to be of considerable benefit in the primary pre-
vention of cardiovascular disease.
Summary
For a population without history of cardiovascular dis-
ease or antihypertensive medication use, genetically 
proxied blood pressure reduction was associated with 
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Surveys Classification of Surgical Operations and Procedures 
(fourth revision) codes to identify events (Table S1 in the Data 
Supplement). For individuals with multiple incident events (eg, 
incident CAD and incident stroke), the first event recorded 
was used. Related individuals (kinship coefficient, >0.0884) 
and those with prevalent CVD (identified through hospitaliza-
tion codes and self-report) were excluded from the analyses. 
Individuals taking antihypertensive medications at baseline (UK 
Biobank field 20003) were also excluded from the analyses 
because their observed blood pressure is not reflective of their 
genetically predicted blood pressure, thus introducing bias into 
the nonlinear MR estimates.15,17
Candidate Instrumental Variables
For our primary analysis, we selected 253 uncorrelated (r2<0.1) 
single-nucleotide polymorphisms as candidate instrumental 
variables for SBP and DBP based on their previously published 
associations with blood pressure traits.20 Their associations with 
SBP and DBP were estimated in a genome-wide association 
study of 299 024 European ancestry individuals performed by 
the International Consortium of Blood Pressure study, which did 
not include UK Biobank participants.20 Using the coefficients 
for association with SBP and DBP (Table S2), a weighted allele 
score for each participant was created by multiplying the blood 
pressure–increasing allele dosage with the variant’s associa-
tion with SBP or DBP, respectively, and summing across the 
253 variants. The above genetic association estimates were 
taken from a study that adjusted for body mass index. As this 
could theoretically bias the analyses,21 we further performed 
a sensitivity analysis that selected variants from a genome-
wide association study meta-analysis of 2 non-UK Biobank 
cohorts that did not adjust for body mass index (n=122 361; 
Methods in the Data Supplement). Fixed-effects meta-analysis 
was performed using METAL,22 and variants reaching genome-
wide significance (P<5×10−8) were clumped to correlation 
r2<0.01 using PLINK.23 We extracted 22 uncorrelated variants 
as instrumental variables for SBP and 27 uncorrelated variants 
as instrumental variables for DBP in this sensitivity analysis 
(Tables S3 and S4).
Statistical Analyses
All statistical analyses were performed using R (version 3.6.2). 
Differences in characteristics between UK Biobank popula-
tion subgroups were assessed using a Student t test, Wilcoxon 
rank-sum test, Fisher exact test, or χ2 test as appropriate. We 
performed MR analyses investigating the association between 
genetically proxied blood pressure (either SBP or DBP) and 
incident CVD, CAD, and stroke risk. Analyses were performed 
by modeling a linear relationship between genetically proxied 
blood pressure and the outcomes (linear MR)14,24 and also 
using the fractional polynomial method to test for a nonlinear 
relationship between genetically proxied blood pressure and 
the outcomes (nonlinear MR).15,17
Linear MR
We used the ratio of coefficients method to perform MR analy-
ses that assumed a linear association of genetically proxied 
blood pressure with the risk of incident CVD, CAD, and stroke.25 
This represents the association of the allele score with the car-
diovascular outcome (incident CVD, CAD, or stroke) divided 
by the association of the allele score with the blood pressure 
trait (either SBP or DBP).26 Linear regression was used to esti-
mate the association of the allele score with blood pressure, 
incorporating age, sex, principal components 1 to 10 of genetic 
ancestry, genotyping chip, and assessment center as covari-
ates. The proportion of blood pressure variance explained by 
Table 1. Distribution of Risk Factors for Individuals in the Analyzed Population That Had a Weighted Allele Score for SBP and 
DBP Above and Below the Population Median in the Main and Sensitivity Analyses
Variable
Main analysis (allele score adjusted for BMI) Sensitivity analysis (allele score not adjusted for BMI)

















Age, y; mean (SD) 55.9 (8.0) 55.4 (8.1) 55.8 (8.0) 55.4 (8.1) 55.7 (8.0) 55.6 (8.0) 55.7 (8.0) 55.5 (8.0)
Sex, n (%)
Male 54 642 (43.0) 53 959 (42.4) 53 842 (42.5) 53 533 (42.3) 54 549 (42.9) 54 052 (42.5) 53 770 (42.5) 53 605 (42.3)
Female 72 563 (57.0) 73 246 (57.6) 72 740 (57.5) 73 049 (57.7) 72 653 (57.1) 73 156 (57.5) 72 812 (57.5) 72 977 (57.7)
Socioeconomic status, n (%)*
Quintile 1 27 823 (21.9) 28 066 (22.1) 27 742 (21.9) 27 953 (22.1) 27 744 (21.8) 28 145 (22.1) 27 819 (22.0) 27 876 (22.0)
Quintiles 2–4 78 655 (61.8) 78 287 (61.5) 78 210 (61.8) 77 999 (61.6) 78 562 (61.8) 78 380 (61.6) 78 243 (61.8) 77 966 (61.6)
Quintile 5 20 727 (16.3) 20 852 (16.4) 20 630 (16.3) 20 630 (16.3) 20 896 (16.4) 20 683 (16.3) 20 520 (16.2) 20 740 (16.4)
Smoking index, mean (SD)† 0.4 (0.7) 0.4 (0.7) 0.4 (0.7) 0.4 (0.7) 0.4 (0.7) 0.4 (0.7) 0.4 (0.7) 0.4 (0.7)
BMI, kg/m2; mean (SD) 26.9 (4.5) 26.7 (4.4) 26.9 (4.5) 26.7 (4.4) 26.9 (4.5) 26.9 (4.4) 26.9 (4.5) 26.9 (4.4)
SBP, mm Hg; mean (SD) 134.6 (17.8) 138.3 (18.6) 135.0 (18.0) 137.9 (18.5) 135.5 (18.0) 137.4 (18.5) 135.7 (18.2) 137.3 (18.4)
DBP, mm Hg; mean (SD) 80.9 (9.9) 82.7 (10.1) 80.7 (9.9) 82.9 (10.1) 81.4 (10.0) 82.2 (10.1) 81.3 (10.0) 82.4 (10.1)
Diabetes diagnosed, n (%) 2738 (2.1) 2583 (2.0) 2610 (2.1) 2487 (2.0) 2954 (2.3) 2567 (2.0) 2685 (2.1) 2612 (2.1)
LDL-C, mmol/L; mean (SD) 3.7 (0.8) 3.7 (0.8) 3.7 (0.8) 3.7 (0.8) 3.7 (0.8) 3.7 (0.8) 3.7 (0.8) 3.7 (0.8)
BMI indicates body mass index; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; and SBP, systolic blood pressure.
*Socioeconomic status quintiles according to the Townsend deprivation index combining information on social class, employment, car availability, and housing.
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the allele score and its F statistic were calculated to estimate 
instrument strength.27 Cox proportional hazard regression was 
used to estimate the association of the allele score with the 
outcomes, incorporating age, sex, principal components 1 to 10 
of genetic ancestry, genotyping chip, and assessment center as 
covariates. As sensitivity analyses, we considered each variant 
in the allele score separately and performed MR methods that 
differ in their requisite assumptions regarding the inclusion of 
pleiotropic variants: random-effects inverse-variance weighted 
MR, MR-Egger, weighted median MR, and MR-PRESSO.28 
An intercept term in MR-Egger differing from zero can be 
used to evidence the presence of directional pleiotropy,29 and 
MR-PRESSO is able to identify variants with outlying estimates 
that may in turn be excluded from analyses.30
Nonlinear MR
We applied the fractional polynomial method to investigate for 
evidence of a nonlinear relationship between genetically prox-
ied blood pressure and risk of incident CVD, CAD, and stroke. 
This approach has been described previously in detail15–17 and 
is outlined in Methods in the Data Supplement. Briefly, we 
stratified the population into centiles based on residual blood 
pressure, defined as a participant’s blood pressure minus the 
genetic contribution to blood pressure from the allele score. 
By doing this, we aimed to compare individuals in the popu-
lation who would have similar blood pressure values (values 
in the same centile) if they had the same genetic predispo-
sition. Stratifying on blood pressure directly would introduce 
collider bias to distort estimates, as blood pressure is on the 
causal pathway from the genetic variants to CVD.17,31 For each 
centile, we calculated a linear MR estimate for the association 
of genetically proxied blood pressure with the outcome using 
the ratio of coefficients method, as described above.26 Using a 
flexible semiparametric framework, we then performed a meta-
regression of the linear MR estimates obtained for each centile 
against the mean blood pressure in that centile.16,17 A fractional 
polynomial test was used to investigate whether a nonlinear 
model fit this meta-regression better than a linear model (fur-
ther detailed in Methods in the Data Supplement). A Bonferroni 
correction was applied to account for multiple testing of the 
2 blood pressure traits and 3 outcomes, with P<8×10−3 rep-
resenting statistical significance. We further conducted a pri-
ori–specified subgroup analyses considering men and women 




Figure 1. Nonlinear Mendelian randomization considering genetically proxied systolic blood pressure (SBP) and incident 
cardiovascular outcomes.
Nonlinear Mendelian randomization considering genetically proxied systolic blood pressure (SBP) and incident cardiovascular outcomes: (A) 
all incident cardiovascular disease (CVD) events, (B) incident coronary artery disease (CAD), and (C) incident stroke. Displayed on the x axis 
are SBP values in mm Hg. The y axis shows the hazard ratio for the respective incident cardiovascular event. Reference is set to a population 
mean SBP value of 136.5 mm Hg. Gray lines depict the 95% CI. Fractional polynomial test is a goodness-of-fit test assessing whether any 
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Individuals with elevated blood pressure are more likely to 
be prescribed antihypertensive medications, and, therefore, 
exclusion of these individuals from the main analysis could 
potentially distort MR estimates due to selection effects and 
introduction of collider bias. Inverse probability weighting was, 
therefore, performed in a sensitivity analysis to investigate this, 
as described in Methods in the Data Supplement.
RESULTS
A total of 255 714 participants were included in analyses, 
after excluding 66 011 individuals with a history of anti-
hypertensive medication use and 6506 individuals with a 
history of CVD (but not on antihypertensive medications). 
There were 10 606 incident CVD events, including 8430 
incident CAD events (68.1% International Classification 
of Diseases, Tenth Revision, based) and 2176 incident 
stroke events. The allele score explained 4.8% and 4.5% 
of the variance for SBP and DBP, respectively, corre-
sponding to F statistics of 58.6 and 54.1 and low risk of 
substantial weak instrument bias. The distribution of CVD 
risk factors for individuals in the analyzed population that 
had a weighted allele score for SBP and DBP above 
and below the population median in the main and sen-
sitivity analyses is provided in Table 1. Table S5 provides 
these data for individuals in the top and bottom deciles of 
residual blood pressure in the main analysis.
Linear MR Linear MR analyses identified a st
rong association of both genetically proxied SBP and 
DBP with the cardiovascular outcomes. For a 10-mm Hg 
increase in genetically proxied SBP, the hazard ratio 
(HR) of incident CVD was 1.49 ([95% CI, 1.38–1.61] 
P=7×10−25), incident CAD was 1.50 ([95% CI, 1.38–
1.63] P=2×10−21), and incident stroke was 1.44 ([95% 
CI, 1.22–1.70] P=1×10−5). For a 5-mm Hg increase in 
genetically proxied DBP, the HR of incident CVD was 
1.35 ([95% CI, 1.29–1.42] P=5×10−34), incident CAD 
was 1.36 ([95% CI, 1.26–1.47] P=1×10−15), and inci-
dent stroke was 1.39 ([95% CI, 1.20–1.62] P=2×10−5). 
The MR-Egger test did not detect significant directional 
pleiotropy (Table S6), and MR-PRESSO only identified 




Figure 2. Nonlinear Mendelian randomization considering genetically proxied diastolic blood pressure (DBP) and incident 
cardiovascular outcomes.
Nonlinear Mendelian randomization considering genetically proxied diastolic blood pressure (DBP) and incident cardiovascular outcomes: (A) 
all incident cardiovascular disease (CVD) events, (B) incident coronary artery disease (CAD), and (C) incident stroke. Displayed on the x axis 
are DBP values in mm Hg. The y axis shows the hazard ratio for the respective incident cardiovascular event. Reference is set to a population 
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analysis of genetically proxied SBP and CAD (Table S2). 
Similar MR estimates were obtained in sensitivity analy-
ses (Table S6; Figures S1 and S2).
Nonlinear MR
While in some cases the best-fitting fractional polyno-
mial was a nonlinear function, we observed no evidence 
favoring a nonlinear relationship between genetically 
proxied blood pressure and the cardiovascular outcomes 
over a linear one (Figures 1 and 2). This means that any 
departure from linearity was no greater than would be 
expected by chance due to random variability. Compared 
with the population mean SBP of 137 mm Hg, individu-
als with a genetically proxied SBP of 120 mm Hg had 
a 47% lower risk of incident CVD (HR, 0.53 [95% CI, 
0.49–0.58]; Table 2). Compared with the population 
mean DBP of 82 mm Hg, individuals with a genetically 
proxied DBP of 70 mm Hg had a 53% lower risk of inci-
dent CVD (HR, 0.47 [95% CI, 0.41–0.53]; Table 2). MR 
estimates for population subgroups based on stratifica-
tion into SBP and DBP centiles are provided in Tables 
S7 and S8, respectively.
Subgroup analyses considering men and women 
separately produced similar results to the main analyses 
(Figures 3 and 4). Findings were also similar in the two 
sensitivity analyses: (1) using inverse probability weight-
ing to correct for potential selection bias related to exclu-
sion of individuals taking antihypertensive medications at 
baseline (Figures S3 and S4) and (2) using a different 
set of variants as instruments, which were obtained from 
studies not including the UK Biobank participants, and 
without adjustment for body mass index (Figures S5 and 
S6; and Table S9).
DISCUSSION
By applying nonlinear MR methods in the UK Biobank, 
we were able to examine the shape of the relationship 
between genetically proxied blood pressure and incident 
CVD in a population without a history of CVD or antihy-
pertensive medication use. We found no evidence favor-
ing nonlinear relationships between genetically proxied 
SBP or DBP and risk of the cardiovascular outcomes 
over linear ones. Similar results were obtained when con-
sidering males and females separately.




Hazard ratio 95% CI Hazard ratio 95% CI Hazard ratio 95% CI
SBP, mm Hg Min (102.9) 0.28 0.23–0.33 0.21 0.15–0.29 0.42 0.29–0.63
110 0.36 0.32–0.42 0.3 0.24–0.39 0.49 0.36–0.68
120 0.53 0.49–0.58 0.49 0.43–0.57 0.62 0.50–0.77
130 0.78 0.75–0.81 0.77 0.73–0.81 0.82 0.75–0.90
140 1.14 1.12–1.17 1.16 1.12–1.20 1.13 1.07–1.19
150 1.67 1.56–1.80 1.7 1.52–1.90 1.63 1.30–2.05
160 2.45 2.16–2.78 2.43 2.02–2.93 2.49 1.64–3.79
170 3.59 2.99–4.30 3.41 2.64–4.39 4.02 2.12–7.61
180 5.25 4.16–6.64 4.68 3.40–6.44 6.87 2.84–16.63
190 7.69 5.76–10.26 6.32 4.31–9.26 12.55 3.93–40.10
Max (194.6) 9.15 6.69–12.52 7.16 4.76–10.76 16.65 4.58–60.56
DBP, mm Hg Min (58.6) 0.2 0.15–0.25 0.14 0.09–0.23 0.3 0.16–0.52
60 0.22 0.17–0.28 0.17 0.11–0.26 0.31 0.18–0.54
65 0.32 0.27–0.39 0.28 0.21–0.38 0.39 0.25–0.62
70 0.47 0.41–0.53 0.44 0.36–0.54 0.51 0.37–0.70
75 0.65 0.61–0.70 0.64 0.58–0.72 0.67 0.55–0.81
80 0.9 0.88–0.91 0.9 0.87–0.92 0.9 0.85–0.95
85 1.21 1.17–1.24 1.21 1.15–1.26 1.23 1.11–1.35
90 1.6 1.48–1.72 1.57 1.41–1.75 1.71 1.32–2.21
95 2.08 1.85–2.35 1.99 1.68–2.35 2.42 1.58–3.70
100 2.68 2.28–3.14 2.45 1.97–3.06 3.5 1.92–6.39
105 3.4 2.78–4.15 2.97 2.28–3.88 5.16 2.35–11.34
Max (111.7) 4.6 3.58–5.89 3.72 2.70–5.14 8.88 3.11–25.27
Reference is made to a population mean SBP value of 136.5 mm Hg and a population mean DBP value of 81.8 mm Hg. CAD indicates coronary artery disease; CVD, 
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Blood pressure control represents a global health 
challenge,33 and hypertension thresholds have been low-
ered in recent consensus guidelines.34 The MR estimates 
obtained in this study may be used to quantify the effect 
of a persistent, lifelong reduction in blood pressure on 
the primary prevention of CVD and highlight the poten-
tial gains of clinical and public health interventions that 
achieve this. Importantly, they support the notion that for 
a population without a history of CVD or antihypertensive 
medication use, a similar relative reduction in CVD risk 
will be observed irrespective of baseline blood pressure, 
including for individuals who have normal blood pressure.35 
This means that fixed changes in blood pressure will lead 
to similar changes in CVD risk on the HR scale. On the 
absolute scale, risk reduction will be greater for those 
with a higher baseline blood pressure. This finding is con-
sistent with previous large-scale observational analyses 
performed in individuals free of CVD at baseline.6,7 In con-
trast, excessive blood pressure reduction in patients with 
atherosclerotic disease can reduce organ perfusion and 
increase CVD risk,12 and it is, therefore, important that our 
findings are not extrapolated to infer the effect of blood 
pressure lowering in individuals with preexisting CVD. It 
is also important to appreciate that absolute risk reduc-
tion conferred from blood pressure lowering will remain 
greatest for those with the highest blood pressure. Our 
current data support the concept that risk factor targeting 
in low- and medium-risk individuals on a population-wide 
level is likely to also substantially contribute to reducing 
the burden of CVD.36,37 Dietary modification and reduced 
sodium consumption represent examples of public health 
strategies that can be adopted to achieve this.38,39
We found no evidence for a J-shaped association 
of either genetically proxied SBP or DBP with any of 
the outcomes. This contrasts the findings of a recent 
observational study using data from 1.3 million general 
outpatients with a low prevalence of CAD,8 which identi-
fied a J-shaped association of blood pressure with the 
composite outcome of myocardial infarction and stroke. 
This J shape was only partially attenuated after adjusting 
A CB
D FE
Figure 3. Nonlinear Mendelian randomization considering genetically proxied systolic blood pressure (SBP) and incident 
cardiovascular outcomes split by sex. Figure panels:
Nonlinear Mendelian randomization considering genetically proxied systolic blood pressure (SBP) and incident cardiovascular outcomes split 
by sex: (A) all incident cardiovascular disease (CVD) events in men, (B) incident coronary artery disease (CAD) in males, and (C) incident 
stroke in men. D–F, Equivalent analyses in women. Displayed on the x axis are SBP values in mm Hg. The y axis shows the hazard ratio for the 














8  June 2021 Hypertension. 2021;77:00–00. DOI: 10.1161/HYPERTENSIONAHA.120.16534
Malik et al Shape of the BP-Incident CVD Relationship
for age, ethnicity, and comorbidities,8 and there remains 
the possibility that residual unknown or unmeasured 
confounding factors are responsible for the discrepancy 
with our findings. A systematic review and meta-analysis 
of blood pressure–lowering trials considering 613 815 
participants from 123 studies found no trend for CVD 
risk reduction per 10 mm Hg lower SBP when stratifying 
trials by mean baseline SBP.3 In the SPRINT trial, SBP 
lowering to <120 mm Hg as compared with 140 mm Hg 
resulted in fewer major cardiovascular events.11 The find-
ings from our current MR study additionally support a 
relative CVD risk reduction from blood pressure lowering 
below this level in patients without a history of CVD.
Our study has a number of strengths. By employing ran-
domly allocated genetic variants as proxies for the effect 
of modifying blood pressure, we were able to use the MR 
paradigm to overcome the environmental confounding 
bias that can limit causal inference in observational asso-
ciation studies. The implementation of both linear and non-
linear MR methods within the comprehensive UK Biobank 
resource enabled us to efficiently study the relationships 
of genetically proxied SBP and DBP with incident CVD, 
CAD, and stroke, including in sex-stratified analyses. 
Importantly, the fractional polynomial method allowed us 
to investigate for evidence of nonlinear associations.
Our study also has limitations. This work only con-
sidered participants without a history of CVD or antihy-
pertensive medication use, and its findings should not 
be extrapolated to populations with established CVD.9,10 
Individuals that reported taking antihypertensive medica-
tions were excluded to allow for meaningful stratifica-
tion into blood pressure quantiles, and as such, there is 
the possibility that ascertainment bias may have been 
introduced. Reassuringly, similar findings were obtained 
in inverse probability weighting sensitivity analyses, sug-
gesting that any such bias is unlikely to be affecting our 
conclusions. The employed MR approach assumes that 
the genetic variants utilized as proxies for blood pressure 
do not affect CVD risk through alternative (pleiotropic) 
pathways—an assumption that cannot be tested and if 
A CB
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Figure 4. Nonlinear Mendelian randomization considering genetically proxied diastolic blood pressure (DBP) and incident 
cardiovascular outcomes split by sex. 
Nonlinear Mendelian randomization considering genetically proxied diastolic blood pressure (DBP) and incident cardiovascular outcomes 
split by sex: (A) all incident cardiovascular disease (CVD) events in men, (B) incident coronary artery disease (CAD) in men, and (C) incident 
stroke in men. D–F, Equivalent analyses in women. Displayed on the x axis are DBP values in mm Hg. The y axis shows the hazard ratio for the 
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violated could introduce bias to the obtained estimates. 
Our used MR method also explores the effects of life-
long changes in blood pressure, and its estimates should, 
therefore, not be extrapolated to quantify the effect of 
blood pressure modification in adult life, such as through 
use of antihypertensive medications. Finally, there were 
differences in the distribution of risk factors between 
individuals in the highest and lowest deciles of residual 
blood pressure (Table S5), suggesting that this MR analy-
sis may still be vulnerable to environmental confounding.
PERSPECTIVES
For a population without a history of CVD or antihyper-
tensive medication use, genetically proxied blood pres-
sure reduction was associated with lower CVD risk at all 
levels of blood pressure. These findings provide evidence 
to support that public health interventions achieving per-
sistent, population-wide blood pressure reduction will be 
of considerable benefit in the primary prevention of CVD.
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